...
机译:199例骨髓增生性肿瘤患者TET2突变的细胞遗传学相关性† sup>
Division of Hematology, Hematopathology, and Cytogenetics, Departments of Medicine and Laboratory Medicine, Mayo Clinic, Rochester, Minnesota;
Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York|Leukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York;
Division of Hematology, Hematopathology, and Cytogenetics, Departments of Medicine and Laboratory Medicine, Mayo Clinic, Rochester, Minnesota;
Division of Hematology, Hematopathology, and Cytogenetics, Departments of Medicine and Laboratory Medicine, Mayo Clinic, Rochester, Minnesota;
Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York|Leukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York;
Division of Hematology, Hematopathology, and Cytogenetics, Departments of Medicine and Laboratory Medicine, Mayo Clinic, Rochester, Minnesota;
Division of Hematology, Hematopathology, and Cytogenetics, Departments of Medicine and Laboratory Medicine, Mayo Clinic, Rochester, Minnesota;
Division of Hematology, Hematopathology, and Cytogenetics, Departments of Medicine and Laboratory Medicine, Mayo Clinic, Rochester, Minnesota;
机译:199例骨髓增生性肿瘤患者TET2突变的细胞遗传学相关性。
机译:骨髓肿瘤中的克隆因子与形态发生突变:U2AF1,TET2,CSF3R和JAK2“共突变”肌酚肌肉瘤中的年代观察表明激酶抑制剂治疗反应的突变和潜在预测值的分层顺序。
机译:对TET2和JAK2突变的克隆分析表明,TET2可能是骨髓增生性肿瘤进展中的晚期事件。
机译:MicroRNA介导的骨髓增生性肿瘤中TET2相互作用网络的改变。
机译:慢性骨髓增生性肿瘤钙网蛋白基因突变的临床和病理意义
机译:在199例骨髓增生性肿瘤TET2突变的细胞遗传学相关因素
机译:199例髓原肿瘤患者TET2突变的细胞遗传学相关性